Eli Lilly and Company, a global leader in pharmaceutical development, has announced a significant acquisition of Morphic Holding, Inc., a biopharmaceutical company specializing in oral integrin therapies. The deal, valued at $3.2 billion, aims to enhance Eli Lilly’s portfolio, particularly in the treatment of inflammatory bowel diseases (IBD). This acquisition is seen as a strategic move to strengthen Eli Lilly’s position in the biotech sector and expand its therapeutic offerings.
Background Information
Eli Lilly and Company
Founded in 1876, Eli Lilly is one of the oldest and most established pharmaceutical companies globally, known for its innovative treatments for various diseases including diabetes,
